Tailoring mTOR-Based Therapy: Molecular Evidence and Clinical Challenges

10.7164/antibiotics.28.727

10.7164/antibiotics.28.721

10.1021/bi00123a031

10.1128/mcb.11.3.1718-1723.1991

10.1128/mcb.13.10.6012-6023.1993

10.1016/0092-8674(93)90144-F

10.1038/369756a0

10.1126/science.270.5233.50

10.1073/pnas.92.11.4947

10.1126/science.273.5272.239

10.1016/j.cell.2012.03.017

10.1128/MCB.21.15.5050-5062.2001

10.1210/mend.14.6.0446

10.1126/science.1106148

10.1161/01.CIR.0000129768.35536.FA

10.1042/BST0370217

10.1111/j.1365-2141.2009.07595.x

10.1016/j.drudis.2006.12.008

10.1161/01.RES.76.3.412

10.1016/S0021-9258(18)53755-8

10.1016/j.molcel.2006.03.029

10.1172/JCI119038

Morris RE , CaoW, HuangX et al. Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells. Transplant. Proc. 27(1) , 430–431 (1995).

10.1161/01.CIR.99.16.2164

10.1038/nrd2924

10.1056/NEJMoa1001671

10.2217/fon.12.146

10.1586/era.11.93

10.1056/NEJMoa1109653

10.1200/jco.2013.31.15_suppl.505

10.1056/NEJMoa066838

10.1200/JCO.2008.20.7977

10.1038/ki.1996.28

10.3389/fnmol.2011.00051

10.3322/caac.20003

10.1126/scisignal.267pe24

10.1074/jbc.M900301200

10.1073/pnas.0809136105

10.1172/JCI37539

Carracedo A , MaL, Teruya-FeldsteinJ et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118(9) , 3065–3074 (2008).

10.1007/s10549-011-1420-7

10.1016/j.molcel.2011.01.030

10.1007/s11523-011-0177-6

10.1073/pnas.171076798

10.1158/0008-5472.CAN-08-1522

10.1200/JCO.2005.13.466

10.1038/nm0202-128

10.1023/B:APPT.0000045781.46314.e2

10.1158/0008-5472.CAN-11-2195

10.1016/j.cell.2012.02.005

10.2217/pgs.10.26

Cavarretta E , ChiarielloGA, CondorelliG. Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra. Eur. Heart J. (2013) (Epub ahead of print).

10.1074/jbc.M112.416446

10.4161/cc.24100

Li C , LiuY, LiuJ et al. Rapamycin inhibits human glioma cell proliferation through down-regulating mammalian target of rapamycin pathway and up-regulating microRNA-143. Head Neck Oncol. 4(3) , 66 (2012).

10.3892/etm.2012.787

10.1002/jcb.24504

10.1083/jcb.200912093

10.1083/jcb.201007165

10.1002/hep.25576

10.1186/1471-2407-12-546

Yan B , FuQ, LaiL et al. Downregulation of microRNA 99a in oral squamous cell carcinomas contributes to the growth and survival of oral cancer cells. Mol. Med. Rep. 6(3) , 675–681 (2012).

10.2337/db12-0451

10.1038/onc.2011.63

10.1093/carcin/bgs288

10.1158/0008-5472.CAN-11-0368

10.1161/CIRCULATIONAHA.110.000323

10.1210/me.2009-0295

10.1128/JVI.00961-08

10.1158/0008-5472.CAN-09-3970

10.1007/s12032-012-0411-9

10.1073/pnas.1009719107

10.1158/0008-5472.CAN-10-0145

10.1158/1535-7163.MCT-10-1099

10.1182/blood-2011-04-346601

10.1167/iovs.09-3445

10.1158/0008-5472.CAN-09-1751

10.1038/leu.2011.339

10.1002/pbc.22935

10.1038/bjc.2012.368

10.1158/1078-0432.CCR-11-2750

10.1016/j.bmcl.2013.01.019

Maira SM , FinanP, Garcia-EcheverriaC. From the bench to the bed side: PI3K pathway inhibitors in clinical development. Curr. Top. Microbiol. Immunol.347 , 209–239 (2010).

10.1021/jm901830p

10.1158/1535-7163.MCT-12-0015

10.1158/1535-7163.MCT-11-0185

10.1158/1535-7163.MCT-08-0017

10.1158/0008-5472.CAN-10-1814

10.1124/mol.112.080408

10.1126/scitranslmed.3003923

10.1002/ijc.28023

Clinicaltrials.gov. http://clinicaltrials.gov